Breakthroughs Blog

Breakthroughs brings you stories of bright ideas and bold innovations in global health.

The Latest
Ansley Kahn
Research Roundup: Scientists release sterile mosquitoes in Burkina Faso, Themis raises $44 million for phase 3 chikungunya vaccine trial, and Merck's Ebola vaccine tees up FDA date

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Recent

GHTC/Marissa Chmiola
GHTC briefing highlights critical role of US government in advancing global health innovation in an increasingly globalized world

On Tuesday, GHTC launched our seventh annual policy report through a congressional briefing and panel discussion. The critical role played by the US government in catalyzing global health research and development was a recurring theme, as panelists discussed the interconnectedness of global and American health and emphasized the need for new health tools to protect against outbreaks and continue progress.

GHTC
Read More
PATH/A. Golden
Research Roundup: an affordable hepatitis C regimen, rapid diagnostics for neglected diseases, and fighting Zika with tires and milk

GHTC member the Drugs for Neglected Diseases initiative will test an affordable hepatitis C regimen in Malaysia and Thailand, with a guarantee from generic drug manufacturer Pharco Pharmaceuticals that, if successful, the product will be priced at no more than US$294 for the entire regimen.

GHTC
Read More
Funding by crisis is no cure for global health threats

The Zika virus outbreak reinforces the need for US policymakers to stop funding by crisis and commit to sustainable, long-term investment in global health R&D.

GHTC
Read More
Research Roundup: legislation to expedite antibiotic R&D, a graduated approach to drug patents, and more

Scientists have described the first “teenage” broadly neutralizing antibody—an early stage version of the molecule, before developing the traits that make it effective against manifold HIV strains.

GHTC
Read More
President will redirect Ebola funds for Zika, but where is the money from and where will it go?

The Administration announced that it will transfer nearly $600 million in remaining Ebola funds to fight the growing threat of Zika virus. But many questions remain. Where is the money going? What accounts is it coming from? And what does this mean for the Global Health Security Agenda?

GHTC
Read More
Research Roundup: Mosquitos and mice in the fight against Zika

Is it feasible or wise to eradicate mosquitoes? Could genetically-modified mosquitoes help researcher tackle the Zika virus? Learn more in this week's Research Roundup.

GHTC
Read More
Research Roundup: Identifying people at-risk for TB, a device to aid IUD insertion, and vaccines against cancer

In this week's Research Roundup, we look at gene risk for tuberculosis, a new tool to help with inserting IUDs, and vaccines to prevent and treat cancer.

GHTC
Read More
Take 1.5 minutes for 1.5 million lives

In this guest post, Dara Erck, vice president of External Affairs at Aeras, a global nonprofit biotechnology organization, highlights a new video launched on World TB Day to raise awareness of the urgent need for new tools to combat tuberculosis (TB).

Aeras
Read More
Research Roundup: cash prizes for R&D, genetically modified mosquitoes, and drones for rapid diagnosis

US Senator Bernie Sanders (I-VT) released a plan last week as part of his Democratic presidential bid to incentivize research and development (R&D) for new HIV/AIDS medicines while ensuring they remain affordable.

GHTC
Read More
Research Roundup: antibiotic resistance in preemies, a low-cost TB test, and more

A new study out of the Washington University School of Medicine in St. Louis, Missouri, revealed a proliferation of antibiotic-resistant bacteria in the gastrointestinal tracts of premature infants.

GHTC
Read More
Innovative health tools put the power of protection in women’s hands

This International Women’s Day, GHTC is celebrating two novel, female-initiated health technologies that have the potential to give women and girls greater control over their sexual and reproductive health, empowering them to make informed decisions about whether and when to have children and to protect themselves and their families from HIV and other sexually transmitted infections (STIs).

GHTC
Read More
Better together? Five takeaways on the proposal for a WHO pooled fund

Last week, GHTC convened a panel of experts to dissect and discuss a proposal for pooled funding for global health research and development (R&D).

Read More
Research Roundup: A novel single-pill HIV treatment, a promising Ebola therapy, and a collaboration between Google and UNICEF to map Zika

Gilead Sciences, a California-based biopharmaceutical company, has received US Food and Drug Administration (FDA) approval for Odefsey®, a complete, single-pill regimen for HIV/AIDS.

GHTC
Read More
Research Roundup: A vaginal ring to prevent HIV, antibodies against Ebola, and the US response to malaria

GHTC member the International Partnership for Microbicides (IPM) announced last week the results of two phase 3 clinical trials demonstrating that a monthly vaginal ring filled with the antiretroviral drug dapivirine can reduce the risk of HIV infection in women.

GHTC
Read More
Research Roundup: Vaccines for Rift Valley Fever, MERS, and Zika

A vaccine candidate against Rift Valley Fever appears to be safe and effective for livestock and has the potential for use in humans.

GHTC
Read More
A vaccine is essential to conclusively end HIV/AIDS: New modeling data catalyzes conversations around the end of HIV/AIDS and a vaccine’s role in getting there

In this guest post Tom Harmon, senior policy analyst at the International AIDS Vaccine Initiative (IAVI), highlights a new analysis exploring the critical role of a vaccine in ending AIDS.

Read More
Research Roundup: Thermal blankets for preemies, remote critical care, and mechanisms to accelerate Zika R&D

Many of the 15 million babies born premature each year struggle with hypothermia and need help to stay warm.

GHTC
Read More
WHO says “no thanks” to the private sector

There’s an old adage about political negotiating: “You need to be in the room when things are happening if you want to have an impact.”

Read More
Ebola funding boost hides ongoing decline in neglected disease R&D

In this guest post, Anna Doubell, an analyst at Policy Cures, writes about the findings of this year’s G-FINDER report on neglected disease research and development (R&D). Supporting data from the report was released this week and is now available online through the G-FINDER public search tool.

Policy Cures
Read More
CDC/Dr. Scott Smith
Global health R&D in the President’s FY17 budget request

On Monday, President Obama released his proposed budget for fiscal year 2017 (FY17).

GHTC
Read More